Purpose-built AI
InfinityAI leverages advanced AI to unlock clinically meaningful insights and novel biomarkers from complex, multimodal, longitudinal data.
Identify more patients eligible for a therapy with a novel biomarker
61% post 1st line ET ESR1- patients that still benefit from SERD therapy
*Across Guardant360 and Reveal tests.
CRC, colorectal cancer; GEJ, gastroesophageal junction; NSCLC, non-small cell lung cancer; PFS, progression-free survival; SCLC, small cell lung cancer; RWD, real-world data.
Get Cancer Tumor Type Predictions from Molecular Testing
HomeGuardant Infinity™ for BioPharma Guardant360® CDx for BioPharma GuardantINFORM™ for BioPharma